GSK Stays Ahead Of AstraZeneca With New Survival Data In Endometrial Cancer

The companies are competing to prove the value of their PD1/L1 therapies in all endometrial cancer patients - but questions remain about the benefits of adding PARP inhibitors with the latest data from the RUBY and DUO-E Phase III studies.